VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

Autologous Dendritic Cell-Tumor Fusion Vaccine

Vaccine Information

Vaccine Name: Autologous Dendritic Cell-Tumor Fusion Vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007577
Type: Recombinant vector vaccine
Status: Clinical trial
Host Species for Licensed Use: Human
Host Species as Laboratory Animal Model: Human
MUC1 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
CD38 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
SDC1 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
Preparation: DCs were generated from adherent mononuclear cells cultured with granulocyte-macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor-α and fused with myeloma cells obtained from marrow aspirate (Rosenblatt et al., 2011).
Description: A therapeutic cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous tumor cells with potential immunostimulatory and antineoplastic activities. Autologous dendritic cell-tumor fusion vaccine is generated in vitro by mixing DCs and irradiated tumor cells harvested from individual patients and treating them with polyethylene glycol (PEG) to produce DC-tumor cell fusion hybrid cells. Upon administration, autologous dendritic cell-tumor fusion vaccine may elicit antitumor humoral and cellular immune responses. (NCIT_C74016).

This vaccine has been clinical trials involving multiple myeloma. (Rosenblatt et al., 2011)

Host Response

References

NCIT_C74016: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74016]

Rosenblatt et al., 2011: Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011; 117(2); 393-402. [PubMed: 21030562].